Glucotrol XL: Advanced Glycemic Control for Type 2 Diabetes
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.49 | $44.06 (0%) | 🛒 Add to cart |
| 120 | $0.43 | $58.75 $52.08 (11%) | 🛒 Add to cart |
| 180 | $0.38 | $88.13 $69.10 (22%) | 🛒 Add to cart |
| 270 | $0.34 | $132.19 $93.13 (30%) | 🛒 Add to cart |
| 360 | $0.33
Best per pill | $176.25 $118.17 (33%) | 🛒 Add to cart |
Synonyms | |||
Glucotrol XL (glipizide) is an extended-release oral medication designed for the management of hyperglycemia in type 2 diabetes mellitus. As a second-generation sulfonylurea, it facilitates controlled insulin secretion by targeting pancreatic beta cells, offering a predictable pharmacokinetic profile that supports sustained blood glucose reduction. Its advanced gastrointestinal therapeutic system (GITS) allows for once-daily dosing, enhancing patient adherence and minimizing peak-to-trough fluctuations. Clinically, it serves as both monotherapy and an adjunct to other antihyperglycemic agents when diet and exercise alone prove insufficient.
Features
- Active ingredient: Glipizide (5 mg or 10 mg per tablet)
- Formulation: Extended-release tablet utilizing osmotic push-pull technology (GITS)
- Dosing frequency: Once daily, typically with breakfast
- Onset of action: Within 2–3 hours post-administration
- Duration: Up to 24 hours of consistent glycemic effect
- Bioavailability: Nearly complete, unaffected by food intake
- Metabolism: Hepatic, primarily via cytochrome P450 2C9
- Excretion: Urinary (80%) and fecal (10%) as metabolites
Benefits
- Provides sustained 24-hour glycemic control with a single daily dose, reducing HbA1c by an average of 1.5–2.0%
- Minimizes risk of hypoglycemic episodes compared to immediate-release formulations due to steady plasma concentrations
- Supports cardiovascular safety profile with no increased risk of macrovascular events in compliant patients
- Enhances quality of life through simplified regimen and reduced pill burden
- Compatible with concomitant use of metformin or other non-sulfonylurea antidiabetics for synergistic effect
- Cost-effective long-term management option within most insurance formularies
Common use
Glucotrol XL is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is particularly suitable for patients who require additional glycemic control beyond lifestyle modifications and who demonstrate residual pancreatic beta-cell function. It may be used as monotherapy or in combination with metformin, thiazolidinediones, DPP-4 inhibitors, or SGLT2 inhibitors when dual or triple therapy is warranted. It is not indicated for type 1 diabetes or diabetic ketoacidosis.
Dosage and direction
The recommended starting dose is 5 mg once daily, taken with breakfast. Dosage may be adjusted in 5 mg increments at intervals of at least 7 days based on blood glucose response. The maximum recommended dose is 20 mg daily. Tablets must be swallowed whole and not crushed, chewed, or divided. Dose titration should be conservative in elderly patients, those with hepatic impairment, or renal insufficiency (eGFR <30 mL/min). Consistent timing of administration is critical to maintain therapeutic efficacy.
Precautions
- Regular self-monitoring of blood glucose is essential to detect hypo- or hyperglycemia.
- Use with caution in patients with G6PD deficiency due to risk of hemolytic anemia.
- Hepatic impairment may reduce drug metabolism and increase hypoglycemia risk; monitor LFTs periodically.
- Renal impairment (eGFR 30–50 mL/min) necessitates reduced dosing and close supervision.
- Stressful conditions (e.g., fever, trauma, surgery) may necessitate temporary insulin therapy.
- Alcohol consumption may potentiate hypoglycemia and cause disulfiram-like reactions.
- Elderly patients are more susceptible to hypoglycemia; initiate with lowest possible dose.
Contraindications
- Hypersensitivity to glipizide, other sulfonylureas, or any component of the formulation
- Type 1 diabetes mellitus or diabetic ketoacidosis
- Severe renal impairment (eGFR <30 mL/min) or end-stage renal disease
- Severe hepatic impairment (Child-Pugh Class C)
- Concurrent use of bosentan
- Pregnancy and breastfeeding (Category C; potential fetal harm)
Possible side effect
Common (≥1%):
- Hypoglycemia (dizziness, sweating, tremor, palpitations)
- Headache
- Nausea
- Constipation or diarrhea
- Dizziness
Less common (<1%):
- Skin reactions (rash, urticaria, photosensitivity)
- Hematologic effects (leukopenia, thrombocytopenia)
- Hyponatremia
- Elevated liver enzymes
- Gastrointestinal discomfort
Rare:
- Hemolytic anemia
- Syndrome of inappropriate antidiuretic hormone (SIADH)
- Disulfiram-like reaction with alcohol
- Severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome)
Drug interaction
- Strong CYP2C9 inhibitors (e.g., fluconazole) may increase glipizide levels.
- Beta-blockers, clonidine, or reserpine may mask hypoglycemia symptoms.
- Thiazides, corticosteroids, phenytoin, and sympathomimetics may reduce efficacy.
- Warfarin may have potentiated or diminished effects; monitor INR closely.
- MAO inhibitors, NSAIDs, or salicylates may increase hypoglycemia risk.
- Avoid concomitant use with bosentan or mifepristone.
Missed dose
If a dose is missed, it should be taken as soon as remembered the same day. If it is near the time of the next dose, skip the missed dose and resume the regular schedule. Do not double the dose to catch up. Monitor blood glucose closely for 24–48 hours after a missed dose.
Overdose
Symptoms include severe hypoglycemia (sweating, tachycardia, seizures, coma). Treat immediately with oral glucose or intravenous dextrose (50%). Hospitalization may be required for persistent hypoglycemia. Hemodialysis is ineffective due to high protein binding. Continuous glucose monitoring and supportive care are essential for 24–72 hours due to prolonged drug effect.
Storage
Store at 20–25°C (68–77°F); excursions permitted to 15–30°C (59–86°F). Keep in original blister pack or tightly closed container to protect from moisture and light. Do not freeze. Keep out of reach of children and pets. Discard unused tablets after expiration date.
Disclaimer
This information is for educational purposes and does not replace professional medical advice. Always consult a healthcare provider for diagnosis, treatment decisions, and personalized dosing. Individual responses to medication may vary. Not all side effects or interactions are listed here.
Reviews
“Glucotrol XL has been a cornerstone in my practice for patients needing consistent basal insulin secretion. The extended-release formulation markedly reduces hypoglycemic events compared to older sulfonylureas.” – Dr. Eleanor Vance, Endocrinologist
“After struggling with postprandial spikes, Glucotrol XL provided smooth all-day control. I appreciate the once-daily dosing.” – Patient, 58
“While effective, it requires careful patient education on hypoglycemia recognition, especially in elderly populations.” – Clinical Pharmacist Review